Vancouver-based Isodial International Inc (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) announced it has applied for a listing on the Australia stock exchange (ASX) and expects this to be completed in Q1 2018. It is currently listed in the US, Canada and Frankfurt.
In connection with this listing, the company will issue 4,012,414 common shares on the Australia exchange at $0.25 per share to raise just over C$1 million to invest into expansion into Australia and parts of SE Asia.
“We have seen incredible traction with our flagship product Isoderm in Latin America and we envision similar traction in the Australasia region,” stated Company CEO Marcos Agramont.
The company also reported solid revenues in North America of US$1.4 million for the month of August 2017.
Isodiol is the market leader in pharmaceutical and nutraceutical grade phytochemical compounds and the leader in development of phytochemical consumer products. Their strategy is to develop over the counter and pharmaceutical drugs in America, Latin America, Asia and Europe.
The company stock is up 20% from a year ago to $0.29, with a 52-week range of $0.10-0.46. Market cap is C$26.6, and average daily volume is 309k shares.
Source: Isodial press release